Neurological Surgery Doctors in Livingston, NJ Accepting Medicare

4 Neurological Surgery doctors found. Showing 1 - 4

James Kuanhsin Liu, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 S Orange Ave Ste 265, Livingston, NJ 07039 Phone: 973-577-2888

Dr. Luigi Bassani, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 S Orange Ave, Suite 265, Livingston, NJ 07039 Phone: 973-577-2888    Fax: 973-577-2889

Dr. Abbott J Krieger, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 22 Old Short Hills Road., Livingston, NJ 07039 Phone: 973-994-1002

Dr. Paul R Gigante, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 S Orange Ave, Suite 116, Livingston, NJ 07039 Phone: 973-577-2888

News Archive

Trail of research that led to discovery of aspirin's role in prevention of first heart attack

Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor as well as first recipient of an endowed chair in the new Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a Citation Classic in the current issue of Clinical Chemistry. Hennekens was the founding principal investigator (PI) of the landmark Physician's Health Study and was the first to demonstrate that aspirin prevents a first heart attack.

New study finds that fetus exposed to tobacco smoke faces diabetes risk in adulthood

A fetus exposed to tobacco smoke may be at increased risk for diabetes in adulthood, a new study of adult daughters finds.

Senate version of supplemental war appropriations bill would delay Medicaid regulations, increase FDA funds

The Senate Appropriations Committee on Thursday plans to mark up a supplemental war appropriations bill that will include language to block for one year seven new Medicaid regulations proposed by the Bush administration, as well as additional funds for FDA, CQ Today reports (Higa, CQ Today, 5/7).

Tivozanib overall survival results announced by AVEO and Astellas

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.

Data show a decrease in ozone layer

By merging more than a decade of atmospheric data from European satellites, scientists have compiled a homogeneous long-term ozone record that allows them to monitor total ozone trends on a global scale - and the findings look promising.

Read more Medical News

› Verified 9 days ago